Archive | FAQ’s & Answers RSS feed for this section

Do I have to follow the GCP guidelines when my study does not involve any experimental drug and what is the scope of the SA GCP guidelines?

January 19, 2015

0 Comments

Q: Do I have to follow the GCP guidelines when my study does not involve any experimental drug and what is the scope of the SA GCP  guidelines?

A: “These guidelines focus on the management and regulation of drug trials on human participants. These guidelines have not specifically addressed clinical trials on complementary medicines, traditional medicines, and non-pharmacological interventions including surgical procedures, medical devices and X-rays. However, these guidelines are such that, in the absence of alternatives, the basic principles outlined in this document may be used to guide any research involving human participants, particularly research involving experimental study designs.” The SA GCP guidelines are guided by at least 8 other guidance documents. Most Ethics committees in SA will probably require some proof of GCP training for all research involving human participants regardless of the involvement of experimental or registered drugs in the study.

Reference: SA GCP guidelines, 1.3; p.12

 

Continue reading...

Do we have any guidelines for the payment of trial participants in South Africa?

August 29, 2013

0 Comments

Q: Do we have any guidelines for the payment of trial participants in South Africa?

A: “In South Africa, at present, clinical trial participants tend to be paid R150 per visit. The Medicines Control Council (MCC) has recommended that trial participants be reimbursed a minimum of R150 per trial visit. This recommendation was made at the time that the National Health Research Ethics Council was not formally constituted. While not necessarily intended as a “flat rate”, this approach may have been understood and applied as such by stakeholders. The MCC recommendation has apparent advantages in that it is relatively easy to administer, and it appears fair because most trial participants across the country tend to get paid a similar basic amount unless there are additional specific and justifiable costs. However this approach has a number of disadvantages that may lead to unfairness and inequity.” Please visit http://www.nhrec.org.za/wp-content/uploads/2012/payment_considerations.pdf and read the NHREC take and discussion about this topic.

Reference: NHREC (2012). Payment of trial participants in South Africa: Ethical considerations for Research Ethics Committees (RECs). NHREC.

 

 

Continue reading...

The SA National Clinical Trials Registry

December 14, 2011

0 Comments

Q: What is the SANCTR and why is it important to the researcher?

A: The South African National Clinical Trials Register (SANCTR) covers the full spectrum of clinical trials and provides the public with updated information on trials conducted in SA.

The SANCTR forms part of international calls for making trial information publicly available. The International Committee of Medical Journal Editors, which includes peer reviewed journals from around the world, made a statement that from 1 Jul ’05 no trials will be considered for publication unless they are included on a research register. In Nov ’05 the DOH issued a notice that as from the
1st Dec. 2005 all new clinical trials to be conducted in the country must be registered.

Although it is a requirement for all trials to be registered on the SANCTR, to ensure innovation and competitiveness is not compromised those trials whose primary goals are to assess
major unknown toxicity or determine pharmokinetics (Phase I trials) are excluded from being made publicly available.

All trials however whose primary purpose is to affect clinical practice (Phase III) will be publicly accessible. Sponsors/Principal investigators can apply for an exemption for the public recording of Phase II trials if there is potential for innovation, competitiveness, intellectual property rights to be compromised.

Reference: www.sanctr.gov.za/

Continue reading...